Tumor Biology

, Volume 35, Issue 12, pp 12157–12163 | Cite as

MicroRNA-191 promotes pancreatic cancer progression by targeting USP10

  • Hua Liu
  • Xuan-Fu Xu
  • Yan Zhao
  • Mao-Chun Tang
  • Ying-Qun Zhou
  • Jie Lu
  • Feng-Hou Gao
Research Article


Recent studies have shown that microRNAs, a class of small and noncoding RNA molecules, play crucial roles in the initiation and progression of pancreatic cancer. In the present study, the expression and roles of miR-191 were investigated. Through both gain-of function and loss-of function experiments, a pro-oncogenic function of miR-191 was demonstrated. At the molecular level, bioinformatic prediction, luciferase, and protein expression analysis suggested that miR-191 could inhibit protein levels of UPS10, which suppressed the proliferation and growth of cancer cells through stabilizing P53 protein. Collectively, these data suggest that miR-191 could promote pancreatic cancer progression through targeting USP10, implicating a novel mechanism for the tumorigenesis.


Pancreatic cancer MicroRNA miR-191 UPS10 P53 Gene regulation 


Conflicts of interest


Supplementary material

13277_2014_2521_Fig8_ESM.gif (7 kb)
Supplementary Fig. 1

a Relative expression levels of miR-191 after transfection of miR-191 mimics or negative controls (NC) in SW-1990 cells for 36 h. b, c The cell viability (CCK-8 assays, b) and proliferative potential (BrdU assays, c) was determined in SW-1990 cells transfected with miR-191 mimics or NC. d The cell-cycle phase of SW-1990 cells transfected with miR-191 mimics or NC was analyzed by flow cytometry. e, f Cell migration and invasion abilities were determined in SW-1990 cells. After transfected with miR-191 mimics or NC for 24 h, the SW-1990 cells were seeded in Transwell filters (e) or ECM gel-coated Transwell culture chambers (f) and incubated for 24 h, then the Transwell migration assay (e) or invasion assay (f) were conducted. *P < 0.05; **P < 0.01; ***P < 0.001 compared with NC. (GIF 7 kb)

13277_2014_2521_MOESM1_ESM.tif (600 kb)
High-resolution image (TIFF 600 kb)
13277_2014_2521_Fig9_ESM.gif (5 kb)
Supplementary Fig. 2

a, b The cell viability (CCK-8 assays, a) and proliferative potential (BrdU assays, b) was determined in SW-1990 cells transfected with miR-191 antisense (AS) or negative control (NC). c, d Transwell migration (c) or invasion assays (d) were conducted in SW-1990 cells transfected with miR-191 AS or NC. *P < 0.05; **P < 0.01; ***P < 0.001 compared with NC. (GIF 4 kb)

13277_2014_2521_MOESM2_ESM.tif (371 kb)
High-resolution image (TIFF 371 kb)
13277_2014_2521_Fig10_ESM.gif (2 kb)
Supplementary Fig. 3

a, b Protein levels of USP10 were determined by western blot in SW-1990 cells transfected with miR-191 mimics (a), antisense (b), or negative control (NC). (GIF 2 kb)

13277_2014_2521_MOESM3_ESM.tif (145 kb)
High-resolution image (TIFF 144 kb)


  1. 1.
    Ma J, Siegel R, Jemal A. Pancreatic cancer death rates by race among US men and women, 1970–2009. J Natl Cancer Inst. 2013;105:1694–700.PubMedCrossRefGoogle Scholar
  2. 2.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;33:281–97.CrossRefGoogle Scholar
  3. 3.
    Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;33:215–33.CrossRefGoogle Scholar
  4. 4.
    Sun T, Kong X, Du Y, Li Z. Aberrant microRNAs in pancreatic cancer: researches and clinical implications. Gastroenterol Res Pract. 2014;2014:386561.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Neureiter D, Jäger T, Ocker M, Kiesslich T. Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol. 2014;20:7830–48.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Naderi E, Mostafaei M, Pourshams A, Mohamadkhani A. Network of microRNAs-mRNAs interactions in pancreatic cancer. Biomed Res Int. 2014;2014:534821.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Qin S, Zhu Y, Ai F, Li Y, Bai B, Yao W, et al. MicroRNA-191 correlates with poor prognosis of colorectal carcinoma and plays multiple roles by targeting tissue inhibitor of metalloprotease 3. Neoplasma. 2014;61:27–34.PubMedCrossRefGoogle Scholar
  8. 8.
    Elyakim E, Sitbon E, Faerman A, Tabak S, Montia E, Belanis L, et al. hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res. 2010;70:8077–87.PubMedCrossRefGoogle Scholar
  9. 9.
    Colamaio M, Borbone E, Russo L, Bianco M, Federico A, Califano D, et al. miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting. J Clin Endocrinol Metab. 2011;96:E1915–24.PubMedCrossRefGoogle Scholar
  10. 10.
    Kent OA, Mullendore M, Wentzel EA, López-Romero P, Tan AC, Alvarez H, et al. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther. 2009;8:2013–24.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Ryu JK, Matthaei H, Dal Molin M, Hong SM, Canto MI, Schulick RD, et al. Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology. 2011;11:343–50.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Di Leva G, Piovan C, Gasparini P, Ngankeu A, Taccioli C, Briskin D, et al. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet. 2013;9:e1003311.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Soncini C, Berdo I, Draetta G. Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10, a novel human ubiquitin specific protease. Oncogene. 2001;20:3869–79.PubMedCrossRefGoogle Scholar
  14. 14.
    Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010;140:384–96.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Niu J, Shi Y, Xue J, Miao R, Huang S, Wang T, et al. USP10 inhibits genotoxic NF-κB activation by MCPIP1-facilitated deubiquitination of NEMO. EMBO J. 2013;32:3206–19.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    He Y, Cui Y, Wang W, Gu J, Guo S, Ma K, et al. Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-miR-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia. 2011;13:841–53.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 2011;147:223–34.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Lin Z, Yang H, Tan C, Li J, Liu Z, Quan Q, et al. USP10 antagonizes c-Myc transcriptional activation through SIRT6 stabilization to suppress tumor formation. Cell Rep. 2013;5:1639–49.PubMedCrossRefGoogle Scholar
  19. 19.
    Zeng Z, Wu HX, Zhan N, Huang YB, Wang ZS, Yang GF, et al. Prognostic significance of USP10 as a tumor-associated marker in gastric carcinoma. Tumour Biol. 2014;35:3845–53.PubMedCrossRefGoogle Scholar
  20. 20.
    Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol. 2001;13:332–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Cairo S, Armengol C, Buendia MA. Activation of Wnt and Myc signaling in hepatoblastoma. Front Biosci (Elite Ed). 2012;4:480–6.CrossRefGoogle Scholar
  22. 22.
    Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 2009;15:283–93.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S, et al. The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol. 2012;40:1733–47.PubMedGoogle Scholar
  24. 24.
    Ling S, Feng T, Jia K, Tian Y, Li Y. Inflammation to cancer: the molecular biology in the pancreas (review). Oncol Lett. 2014;7:1747–54.PubMedCentralPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of GastroenterologyThe Tenth Hospital Affiliated to Tongji UniversityShanghaiChina
  2. 2.Central LaboratoryThe 3rd Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghaiChina

Personalised recommendations